10mg ZD4054 (Zibotentan) PK study in Male, Elderly Chinese Patients with Advanced Solid malignancies
Study identifier:D4320C00041
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open-label, Single-arm Study to Determine the Single and Multiple Dose Pharmacokinetics of 10mg ZD4054 (Zibotentan) Administered Once Daily in Male, Elderly Chinese Patients with Advanced Solid Malignancies
Medical condition
Advanced solid malignancies
Phase
Phase 1
Healthy volunteers
No
Study drug
ZD4054 (Zibotentan)
Sex
Male
Actual Enrollment
15
Study type
Interventional
Age
50 Years +
Date
Study Start Date: 01 Oct 2009
Primary Completion Date: 01 Sept 2010
Study Completion Date: 01 Apr 2011
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 ZD4054 (Zibotentan) 10mg | Drug: ZD4054 (Zibotentan) 10 mg ZD4054 (Zibotentan) once daily on Day1, Day4 to Day15 Other Name: Zibotentan |
Contacts
Investigators
Principal Investigator
Li Jin
The Cancer Hospital Affiliated Fudan University
